BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 34514844)

  • 1. HOXA9-methylated DNA as a diagnostic biomarker of ovarian malignancy.
    Faaborg L; Jakobsen A; Waldstrøm M; Petersen CB; Andersen RF; Steffensen KD
    Biomark Med; 2021 Oct; 15(15):1309-1317. PubMed ID: 34514844
    [No Abstract]   [Full Text] [Related]  

  • 2. Circulating HOXA9-methylated tumour DNA: A novel biomarker of response to poly (ADP-ribose) polymerase inhibition in BRCA-mutated epithelial ovarian cancer.
    Rusan M; Andersen RF; Jakobsen A; Steffensen KD
    Eur J Cancer; 2020 Jan; 125():121-129. PubMed ID: 31865042
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Detection of aberrant methylation of HOXA9 and HIC1 through multiplex MethyLight assay in serum DNA for the early detection of epithelial ovarian cancer.
    Singh A; Gupta S; Badarukhiya JA; Sachan M
    Int J Cancer; 2020 Sep; 147(6):1740-1752. PubMed ID: 32191343
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic Impact of Circulating Methylated Homeobox A9 DNA in Patients Undergoing Treatment for Recurrent Ovarian Cancer.
    Faaborg L; Andersen RF; Waldstrøm M; Henriksen JR; Adimi P; Jakobsen A; Steffensen KD
    Cancers (Basel); 2022 Mar; 14(7):. PubMed ID: 35406538
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Analysis of HOXA9 methylated ctDNA in ovarian cancer using sense-antisense measurement.
    Faaborg L; Fredslund Andersen R; Waldstrøm M; Høgdall E; Høgdall C; Adimi P; Jakobsen A; Dahl Steffensen K
    Clin Chim Acta; 2021 Nov; 522():152-157. PubMed ID: 34419462
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Investigation of HOXA9 promoter methylation as a biomarker to distinguish oral cancer patients at low risk of neck metastasis.
    Uchida K; Veeramachaneni R; Huey B; Bhattacharya A; Schmidt BL; Albertson DG
    BMC Cancer; 2014 May; 14():353. PubMed ID: 24886209
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HOXA9 methylation and blood vessel invasion in FFPE tissues for prognostic stratification of stage I lung adenocarcinoma patients.
    Lissa D; Ishigame T; Noro R; Tucker MJ; Bliskovsky V; Shema S; Beck JA; Bowman ED; Harris CC; Robles AI
    Lung Cancer; 2018 Aug; 122():151-159. PubMed ID: 30032824
    [TBL] [Abstract][Full Text] [Related]  

  • 8. DNA methylation profiling of ovarian carcinomas and their in vitro models identifies HOXA9, HOXB5, SCGB3A1, and CRABP1 as novel targets.
    Wu Q; Lothe RA; Ahlquist T; Silins I; Tropé CG; Micci F; Nesland JM; Suo Z; Lind GE
    Mol Cancer; 2007 Jul; 6():45. PubMed ID: 17623056
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic and diagnostic significance of DNA methylation patterns in high grade serous ovarian cancer.
    Montavon C; Gloss BS; Warton K; Barton CA; Statham AL; Scurry JP; Tabor B; Nguyen TV; Qu W; Samimi G; Hacker NF; Sutherland RL; Clark SJ; O'Brien PM
    Gynecol Oncol; 2012 Mar; 124(3):582-8. PubMed ID: 22115852
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cumulative methylation alternations of gene promoters and protein markers for diagnosis of epithelial ovarian cancer.
    Xing BL; Li T; Tang ZH; Jiao L; Ge SM; Qiang X; OuYang J
    Genet Mol Res; 2015 May; 14(2):4532-40. PubMed ID: 25966226
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A novel multiple biomarker panel for the early detection of high-grade serous ovarian carcinoma.
    Han C; Bellone S; Siegel ER; Altwerger G; Menderes G; Bonazzoli E; Egawa-Takata T; Pettinella F; Bianchi A; Riccio F; Zammataro L; Yadav G; Marto JA; Penet MF; Levine DA; Drapkin R; Patel A; Litkouhi B; Ratner E; Silasi DA; Huang GS; Azodi M; Schwartz PE; Santin AD
    Gynecol Oncol; 2018 Jun; 149(3):585-591. PubMed ID: 29572027
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The clinical significance of HOXA9 promoter hypermethylation in head and neck squamous cell carcinoma.
    Zhou C; Li J; Li Q; Liu H; Ye D; Wu Z; Shen Z; Deng H
    J Clin Lab Anal; 2019 Jun; 33(5):e22873. PubMed ID: 30843252
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HOXA9, PCDH17, POU4F2, and ONECUT2 as a Urinary Biomarker Combination for the Detection of Bladder Cancer in Chinese Patients with Hematuria.
    Wu Y; Jiang G; Zhang N; Liu S; Lin X; Perschon C; Zheng SL; Ding Q; Wang X; Na R; Sun J; Xu J
    Eur Urol Focus; 2020 Mar; 6(2):284-291. PubMed ID: 30309818
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A multiplex biomarker assay improves the diagnostic performance of HE4 and CA125 in ovarian tumor patients.
    Leandersson P; Åkesson A; Hedenfalk I; Malander S; Borgfeldt C
    PLoS One; 2020; 15(10):e0240418. PubMed ID: 33075095
    [TBL] [Abstract][Full Text] [Related]  

  • 15. NID2 and HOXA9 promoter hypermethylation as biomarkers for prevention and early detection in oral cavity squamous cell carcinoma tissues and saliva.
    Guerrero-Preston R; Soudry E; Acero J; Orera M; Moreno-López L; Macía-Colón G; Jaffe A; Berdasco M; Ili-Gangas C; Brebi-Mieville P; Fu Y; Engstrom C; Irizarry RA; Esteller M; Westra W; Koch W; Califano J; Sidransky D
    Cancer Prev Res (Phila); 2011 Jul; 4(7):1061-72. PubMed ID: 21558411
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Methylation status of the gene promoter of cyclin-dependent kinase inhibitor 2A (CDKN2A) in ovarian cancer.
    Abou-Zeid AA; Azzam AZ; Kamel NA
    Scand J Clin Lab Invest; 2011 Nov; 71(7):542-7. PubMed ID: 21728901
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression of the homeobox gene HOXA9 in ovarian cancer induces peritoneal macrophages to acquire an M2 tumor-promoting phenotype.
    Ko SY; Ladanyi A; Lengyel E; Naora H
    Am J Pathol; 2014 Jan; 184(1):271-81. PubMed ID: 24332016
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Engrailed-2 (EN2) - a novel biomarker in epithelial ovarian cancer.
    McGrath SE; Annels N; Madhuri TK; Tailor A; Butler-Manuel SA; Morgan R; Pandha H; Michael A
    BMC Cancer; 2018 Oct; 18(1):943. PubMed ID: 30285763
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Clinical Impact of Methylated Homeobox A9 ctDNA in Patients with Non-Resectable Biliary Tract Cancer Treated with Erlotinib and Bevacizumab.
    Andersen LB; Mahler MSK; Andersen RF; Jensen LH; Raunkilde L
    Cancers (Basel); 2022 Sep; 14(19):. PubMed ID: 36230519
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ultrasound Features Improve Diagnostic Performance of Ovarian Cancer Predictors in Distinguishing Benign and Malignant Ovarian Tumors.
    Chen YN; Ma F; Zhang YD; Chen L; Li CY; Gong SP
    Curr Med Sci; 2020 Feb; 40(1):184-191. PubMed ID: 32166682
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.